Clinical trials: Malignant Neoplasm of Female Breast
Breast Cancer Female
A Study to Identify Breast Cancer (IDBC)
Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX…
- Trial name
- IDBC (NCT04495244)
- Testing
- Syantra DX Breast Cancer
- Where
- 4 sites in Canada, South Korea and 1 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Syantra Inc.
Breast Cancer, Breast Cancer Female
Long-Term Multidisciplinary Physiotherapy for Breast Cancer Survivors: A Randomized Controlled Trial
This multi-center randomized controlled trial (RCT) evaluates the long-term (12-month) effectiveness of a standardized multidisciplinary physiotherapy program versus standard care on persistent pain, upper limb (UL) dysfunction…
- Trial name
- NCT06913244
- Testing
- Multidisciplinary Physiotherapy Program (MD Physio), Standard Physiotherapy Care
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Al Hayah University In Cairo
Breast Cancer Female, Survivorship
Self-acupressure and Zhan Zhuang for Symptom Cluster Management
The proposed study will be a 3-arm, parallel-group randomized controlled trial on the effects of self-acupressure and Zhan-Zhuang for alleviating pain, fatigue, and sleep disturbance in breast cancer survivors.
- Trial name
- NCT06497582
- Testing
- zhan-zhuang, self-acupressure
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Hong Kong Polytechnic University
Breast Cancer, Chronic Myeloproliferative Disorders
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with cancer that has recurred following bone marrow or peripheral stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003887
- Testing
- peripheral blood lymphocyte therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Neoplasm Female
Extended Follow up of the TARGIT-A Trial
All UK patients who participated in the TARGIT-A Trial were initially treated for early breast cancer between 2000-2012. A total of 3451 patients from 33 hospitals in 11 countries participated in the trial and a comparison was…
- Trial name
- TARGIT-X (NCT03501121)
- Where
- 2 sites in United Kingdom
- Volunteers
- 714 people
- Sponsor
- University College, London
Breast Cancer Female
Stick Together - Pilot Intervention Study
This pilot study investigates the acceptability and feasibility of 'Stick Together', a self-guided online intervention, for younger women with breast cancer and their cohabiting partners.
- Trial name
- NCT05760755
- Testing
- Stick Together
- Where
- Denmark
- Volunteers
- 44 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Breast Cancer Metastatic, Breast Cancer Recurrent
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Targeted therapy in the treatment of breast cancer targets HER2 receptor (Human Epidermal growth factor Receptor). HER2 receptor plays an important role in cell growth and differentiation (5).
- Conditions
- Breast Cancer Metastatic, Breast Cancer Recurrent, Breast Cancer Female
- Trial name
- NCT05301010
- Testing
- Faceptor, Herceptin, Docetaxel
- Where
- 2 sites in Vietnam
- Volunteers
- 128 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Female Breast Cancer, Older Adults
Melatonin Supplementation and Exercise Program in Breast Cancer Women
Introduction: Breast cancer (BC) remains the leading cause of cancer in women with nearly 1.4 million new cases worldwide annually and 27.000 in Spain.
- Conditions
- Female Breast Cancer, Older Adults, Exercise Trainning Progrmam
- Trial name
- MEXBSO (NCT06696378)
- Testing
- Melatonin 6 mg
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- University of Valladolid
Advanced Cancer, Ovarian Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT03667716
- Testing
- COM701, COM701 with Opdivo (Nivolumab).
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Compugen Ltd
Breast Cancer Female, Chemotherapy Effect
Monitoring Response to NAC and Prediction of pCR in Breast Cancer Patients Using Optical Imaging
Neoadjuvant chemotherapy (NAC) is the first line treatment for locally advanced breast cancer (BC). Besides making breast conserving surgery feasible, its main aim is to achieve a pathological complete response (pCR).
- Trial name
- NCT04767659
- Testing
- MAMMOT2
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS San Raffaele
Breast Neoplasm, Prostatic Neoplasm
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and non-Hodgkin…
- Conditions
- Breast Neoplasm, Prostatic Neoplasm, Colorectal Neoplasms, Endometrial Neoplasms
- Trial name
- AH-HA (NCT03935282)
- Testing
- AH-HA Tool in the EPIC EHR
- Where
- 12 sites in United States
- Volunteers
- 645 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Breast Cancer, Female Breast Cancer
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
This is a multicenter, randomized, double-blind, placebo-controlled Phase iii clinical study evaluating the efficacy and safety of FCN- 437c in combination with fluvestrant ± goseraline versus placebo in combination with…
- Trial name
- NCT05438810
- Testing
- FCN-437c,Fulvestrant,Goserelin acetate
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Ahon Pharmaceutical Co., Ltd.
Ovarian Neoplasm, Cancer Genetics
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
Background: Certain genetic mutations are linked to higher rates of cancer. It is important for people with these mutations to tell their families about it.
- Conditions
- Ovarian Neoplasm, Cancer Genetics, Breast Cancer
- Trial name
- NCT01374685
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Breast Cancer, Ovarian Cancer
Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation
Despite relevant clinical and/or familial presentations suggesting a hereditary predisposition (early-onset, multiple primary tumors, familial aggregation), targeted genomic analysis based on the phenotype are often non…
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers
- Trial name
- PANEL (NCT02664389)
- Testing
- Genetic analysis
- Where
- France
- Volunteers
- 289 people
- Sponsor
- University Hospital, Rouen
Breast Cancer Female
Delayed Breast Reconstruction by Prepectoral Implant After Lipo-preparation (RM2prepec)
Breast implants associated with the installation of a complementary matrix (of dermal or synthetic origin), showed satisfactory results in term of post-operative follow-up but also aesthetic outcomes.
- Trial name
- RM2prepec (NCT04343820)
- Testing
- Breast reconstruction
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Cancerologie de l'Ouest
Breast Cancer Female
Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
This study is being done to find out whether a nutritional supplement, called BioResponse-DIM (BR-DIM [oral microencapsulated diindolylmethane]), improves the survival for women who have residual cancer cells following surgery…
- Trial name
- NCT01612910
- Testing
- oral microencapsulated diindolylmethane, laboratory biomarker analysis
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
Sarcoma, Synovial, Sarcoma,Soft Tissue
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers
- Conditions
- Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer
- Trial name
- NCT05296564
- Testing
- CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Hadassah Medical Organization
Radiotherapy, Immunotherapy
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
- Conditions
- Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver
- Trial name
- NCT03589339
- Testing
- NBTXR3, SABR, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 145 people
- Sponsor
- Nanobiotix